Image showing multiple pills representing improvement in therapeutic compound oral bioavailability

Poor solubility remains an ongoing challenge in formulation development. Dr. Sridhar Gummudaveli, Director R &D shares insights on lipid-based drug-delivery systems to solve solubility challenges. A Self-Micro Emulsifying Drug Delivery System (SMEDDS) is a lipid-based “preconcentrate” of solubilized drug composed of lipid excipients; surfactants and co-surfactants (hydrophilic or lipophilic), and co-solvents. These formulations can be readily made into softgels or capsules, which have numerous patient experience benefits, as well as formulation benefits of ensuring dose uniformity and offering an established scale-up route. When such formulations are diluted with gastrointestinal fluids, a thermodynamically stable microemulsion is formed, which maintains the drug in solution and prevents its precipitation irrespective of variations in biological conditions (i.e. enzymes,pH, bile salts).The company’s softgel technology has to date enabled more than 50 poorly soluble drugs (NDAs) to be commercialized, leveraging LBDDS and making it one of the most successful advanced drug delivery technologies applied to BCS Class II drugs.



author avatar
Sridhar Gumudavelli
Sridhar Gumudavelli serves as the Vice President of Formulation R&D at Renejix Pharma Solutions, where he brings a wealth of knowledge and experience to the table. His leadership is instrumental in navigating the complex process of drug formulation, leveraging a variety of technologies to enhance drug absorption, bioavailability, and patient compliance.Sridhar’s expertise is not just limited to his hands-on experience; he is also an innovator with several patents filed under his name. These patents reflect his contributions to advancing drug delivery systems, showcasing his ability to tackle some of the most challenging problems in pharmaceutical sciences for the past 30+ years.

Similar Posts